MalattieSostanze chimiche e FarmaciTecniche ed apparecchiature analitiche, diagnostiche e terapeuticheScienze biologicheScienza dell'informazioneAssistenza sanitaria
Chemotherapy-Induced Febrile NeutropeniaNeutropeniaFebbreFebrile NeutropeniaProtocolli ChemoterapiciVomitoAntineoplasticiNauseaTaxoidiAntiemeticiFattore Stimolante Le Colonie Dei GranulocitiAlopeciaNeoplasieSchema Di Somministrazione FarmacologicaMucositePaclitaxelCisplatinoEsito Della TerapiaDoxorubicinaCiclofosfamideAntineoplastici FitogeniciSerotonin 5-HT3 Receptor AntagonistsInfusioni EndovenoseFluorouracileCamptotecinaFebbre Di Origine SconosciutaPiastrinopeniaMalattie Del Sistema Nervoso PerifericoDeossicitidinaStomatiteAgranulocitosiEtoposideCarboplatinoDose Massima TollerataVinblastinaEpirubicinaRelazione Farmacologica Dose-RispostaGranisetroneNeoplasie Della MammellaMicosiNeoplasie EmatologicheNeoplasie Del PolmoneOndansetroneChinuclidineLeucopeniaDrug-Related Side Effects and Adverse ReactionsAmenorreaAnalisi Di SopravvivenzaIfosfamideSopravvivenza Senza MalattiaComposti Organici Del PlatinoMalattie EmatologicheAnemiaVincristinaProfilassi AntibioticaInfezioni BattericheStudi ProspetticiAntraciclineAntimetaboliti AntineoplasticiProteine RicombinantiTasso Di SopravvivenzaAgenti AntibattericiFarmacoresistenza TumoraleCarcinoma Del Polmone Non A Piccole CelluleSostanze Alchilanti AntineoplasticheInfezioni OpportunisteSomministrazione OraleConta Dei LeucocitiChemioterapia Adiuvante

Mortality, length of stay, and cost associated with hospitalized adult cancer patients with febrile neutropenia. (1/10)

BACKGROUND: Febrile neutropenia (FN) is a serious complication following chemotherapy and is associated with significant mortality and financial expenditure. The aim of this study was to evaluate risk factors for longer length of stay (LOS) and mortality and cost of treatment among hospitalized adults with cancer who developed febrile neutropenia in Thailand. MATERIALS AND METHODS: Information on illness of inpatients and casualties came from hospitals nationwide and from hospital withdrawals from the 3 health insurance schemes in fiscal 2010. The data covered 96% of the population and were analyzed by age groups, hospital level, and insurance year schemes in patients with febrile neutropenia. RESULTS: A total of 5,809 patients were identified in the study. The mortality rate was 14%. The median LOS was 8.67 days and 69% of patients stayed for longer than 5 days. On bivariate analysis, age, cancer type, and infectious complications (bacteremia/sepsis, hypotension, fungal infections, and pneumonia) were significantly associated with longer LOS and death. On multivariate analysis, acute leukemia and infectious complications were linked with longer LOS and death significantly. The median cost of hospitalized FN was THB 33,686 (USD 1,122) with the highest cost observed in acute leukemia patients. CONCLUSIONS: FN in adult patients results in significant mortality in hospitalized Thai patients. Factors associated with increased mortality include older age (>70), acute leukemia, comorbidity, and infectious complications.  (+info)

Febrile neutropenia in the tropics: a description of clinical and microbiological findings and their impact on inappropriate therapy currently used at an oncological reference center in Colombia. (2/10)

 (+info)

Performance of serum biomarkers for the early detection of invasive aspergillosis in febrile, neutropenic patients: a multi-state model. (3/10)

 (+info)

Lenalidomide plus cyclophosphamide, doxorubicin, vincristine, prednisone and rituximab is safe and effective in untreated, elderly patients with diffuse large B-cell lymphoma: a phase I study by the Fondazione Italiana Linfomi. (4/10)

 (+info)

Comparison of pegfilgrastim prescribing practice to national guidelines at a university hospital outpatient oncology clinic. (5/10)

 (+info)

Bendamustine combined with rituximab for patients with relapsed or refractory diffuse large B cell lymphoma. (6/10)

 (+info)

Treatment of invasive fungal infections in cancer patients-updated recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO). (7/10)

 (+info)

Study design: two long-term observational studies of the biosimilar filgrastim Nivestim (Hospira filgrastim) in the treatment and prevention of chemotherapy-induced neutropenia. (8/10)

 (+info)